|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The postpartum period is a critical time for both maternal and child health, and more than half of all maternal deaths occur postpartum, from one day to one year after birth. This poor outcome is linked to the racial and ethnic disparities that disproportionately effects low income and black women. To reduce the burden of the postpartum period for this population, the goal of this project is to develop an accessible, targeted online tool designed to address the needs of underserved women who are at greater risk for adverse postpartum outcomes by providing the appropriate tools, knowledge and skills to improve postpartum health.
Description: Measured by the Connor-Davidson Resilience Scale, a 25-item scale covering 17 domains related to resiliency, used with a variety of populations, across a wide range of languages, racial/ethnic, and cultural groups. It has strong psychometric properties and validated short forms. Scoring of the scale is based on summing the total of all items, each of which is scored from 0-4. For the CD-RISC-25, the full range is from 0 to 100, with higher scores reflecting greater resilience.Measure: Change from Baseline Resilience at 4 Weeks Time: baseline, 4 weeks
Description: The Edinburgh Postnatal Depression Scale (EPDS) will be used to assess depressive symptoms. The 10-question Edinburgh Postnatal Depression Scale (EPDS) is a valuable and efficient way of identifying patients at risk for perinatal depression. Scores range from 0-30. Higher scores indicate more depressive symptoms. Mothers who score above 13 are likely to be suffering from a depressive illness of varying severity.Measure: Change from Baseline Depressive Symptoms at 4 Weeks Using the Edinburgh Postnatal Depression Scale (EPDS) Time: baseline, 4 weeks
Description: The Center for Epi Studies of Depression (CES-D) will be used to assess depressive symptoms. The CES-D has been used extensively in culturally diverse populations. The CES-D is a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Scores range from 0 to 60, with high scores indicating greater depressive symptoms.Measure: Change from Baseline Depressive Symptoms at 4 Weeks Using the Center for Epi Studies of Depression (CES-D) Time: baseline, 4 weeks
Description: The Patient Health Question (PHQ-9) will be used to identify major depression. Scores range from 1-27, with higher scores indicating greater severity of depression.Measure: Change from Baseline Depressive Symptoms at 4 Weeks Using the Patient Health Question (PHQ-9) Time: baseline, 4 weeks
Description: The State-Trait Anxiety Inventory (STAI) is a measure of trait and state anxiety with 20 items for assessing trait anxiety and 20 for state anxiety. It has been validated for use with pregnant women. All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). The range of possible scores for form Y of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-T and STAI-S subscales. Higher scores indicate greater anxiety.Measure: Change from Baseline Parent Anxiety at 4 Weeks Time: baseline, 4 weeks
Description: The Behavioral Risk Factor Surveillance System (BRFSS) Historical Questions will be used to address topics including health insurance coverage, continuity, cost barriers, health care visits, and satisfaction with care. Specific questions of interest relevant to this population will be selected by the investigators. Change in individual question responses will be assessed from baseline to 4 weeks.Measure: Change from Baseline Health Care Access and Utilization at 4 Weeks Time: baseline, 4 weeks
Description: Emerging scales on COVID-19 include The Fear of COVID-19 Scale and the Coronavirus Anxiety Scale. Where no validated scales exist, questions will be developed specific to the COVID-19 crisis for this population. Existing scales will be used to inform the development of a study-specific instrument to assess COVID-19 specific fear and anxiety in postpartum women. Specific questions of interest relevant to this population will be selected by the investigators. Change in individual question responses will be assessed from baseline to 4 weeks.Measure: Change from COVID-19 Specific Fear and Anxiety at 4 Weeks Time: baseline, 4 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports